Dose range finding and main efficacy study for one peptide-drug-conjugate using the MDA-MB-231 cell line-based xenograft mouse model of triple negative breast cancer (2022–2024)
- Grant type:
- University of Sydney
- Researchers:
-
-
- Funded by:
- The University of Sydney
